Endogenous Secretory Receptor for Advanced Glycation End Products and Chronic Kidney Disease in the Elderly Population

Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
American Journal of Nephrology (Impact Factor: 2.67). 03/2011; 33(4):313-8. DOI: 10.1159/000324846
Source: PubMed


The relationship of circulating endogenous secretory receptor for advanced glycation end products (esRAGE) and chronic kidney disease (CKD) has not been well characterized. The aim of the study was to determine whether plasma esRAGE is associated with CKD and is predictive of developing CKD in older adults.
The relationship between plasma esRAGE and CKD (more than stage 3 of the National Kidney Foundation classification; estimated glomerular filtration rate <60 ml/min/1.73 m(2)) and CKD over 6 years of follow-up was examined in a cross-sectional and prospective study design in 1,016 men and women, ≥65 years, in the InCHIANTI study, a population-based cohort study of aging in Tuscany, Italy.
At enrollment, 158 (15.5%) had CKD. Mean (SD) plasma esRAGE was 0.45 (0.24) ng/ml. Plasma esRAGE (ng/ml) was associated with CKD (odds ratio per 1 SD = 1.30; 95% CI 1.1-1.6; p < 0.005) in a multivariable logistic regression model, adjusting for potential confounders. Plasma esRAGE was an independent predictor of incident CKD over 6 years of follow-up (hazard ratio per 1 SD = 1.37; 95% CI 1.1-1.7; p < 0.008) in a multivariable Cox proportional hazards model, adjusting for potential confounders.
Elevated plasma esRAGE is independently associated with CKD and is an independent predictor of incident CKD in older community-dwelling adults.

Download full-text


Available from: Ravi Varadhan
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent research has identified that aging and disease are not synonymous and that aging can be optimized. This has been demonstrated in animal models with genetic manipulation and caloric restriction that delay aging, morbidity and mortality. In these systems, mortality rate has been the primary marker of aging, but in vivo markers of aging are needed for human studies. Specifically, biomarkers of primary aging are needed as intermediate outcomes to understand the aging process and potential early benefits of preventive interventions. A useful approach for identifying and testing biomarkers of aging in epidemiologic studies includes demonstrating biologic plausibility that the marker describes a basic aging process, demonstrating the potential for translation from bench to bedside and to population, and subsequently assessing associations with important aging outcomes using optimal epidemiologic study designs and in accord with key statistical considerations. Biomarkers that putatively measure aspects of aging include interleukin-6, leukocyte telomere length, advanced glycation end products, insulin-like growth factor-1, dihydroepiandrostenedione sulfate and klotho. With these tools, epidemiologists will help uncover the secrets to living a healthy, long life and be integral to the design, implementation and assessment of interventions to promote healthy aging. © 2012 Springer Science+Business Media Dordrecht. All rights reserved.
    No preview · Article · Jun 2012
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to examine whether oxidative and AGE-mediated processes correlates with the metabolic changes of proteoglycans (PGs) and proteins during physiological ageing. The age and gender-associated changes of PGs metabolism were evaluated by plasma chondroitin sulfates (CS), dermatan sulfates (DS) and heparan sulfates and heparin (HS/H). We found a linear age-related decline in CS, DS and HS/H, the first one being the predominant plasma GAG during ageing. The possible deleterious effect of oxidative phenomenon on proteins' and proteoglycans' metabolism during ageing process was analyzed by plasma carbonyls (PCO) and thiols (PSH) as well as by total antioxidant capacity (TAS). An age-dependent increase in PCO and decrease in PSH concentrations were found, both strongly correlated with decreasing with age plasma TAS. Intensity of glycation was assessed by circulating N(ε)-(carboxymethyl)lysine (CML) and endogenous secretory receptor for AGE (esRAGE), both of them founding associated with ageing. Moreover, all markers of oxidative and AGE-mediated damage correlated with CS and DS level and could be contributing factors to age-related changes of these GAG types. Thus, plasma CS and DS could become promising biomarkers of human ageing to date, owning to its close association with oxidative status and glycation processes.
    Full-text · Article · Jul 2012 · Mechanisms of ageing and development
  • [Show abstract] [Hide abstract]
    ABSTRACT: Advanced glycation end products (AGEs) was implicated in the pathogenesis of endothelial dysfunction in diabetic vascular complications. Our previous study found that a novel compound 4,4'-diphenylmethane-bis(methyl) carbamate (CM1) from Cortex Mori (Morus alba L.) could attenuate AGEs-induced endothelial dysfunction. The present study was conducted to explore the possible protective mechanisms of CM1 on AGEs-induced endothelium damage. In binding experiments, fluorescence quenching and fluorescence polarization assays showed no significant difference changes of AGEs on fluorescence intensity and polarization in the absence/presence of CM1. In AGEs formation experiments, CM1 was incubated with AGEs precursor compounds methylglyoxal (MGO), glyceraldehydes (Glycer) or glycolaldehyde (Glycol) in the formation system. However, high performance liquid chromatography (HPLC) analysis showed no new conjugated compounds formed in the reaction system. The results of ELISA analysis also showed that CM1 did not inhibit the AGEs formation. However, the pretreatment with CM1 could decrease significantly AGEs or high-mobility group box-1 (HMGB1, a ligand of RAGE)-induced cytotoxicity, apoptosis and reactive oxygen species (ROS) in human umbilical vein endothelial cells (HUVECs). Our results suggested that CM1 might block the AGEs-RAGE signal transduction rather than inhibit AGEs formation or bind to AGEs and change its structure to prevent endothelial dysfunction in diabetic vascular complications.
    No preview · Article · Jun 2013 · Fitoterapia
Show more